Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands.
B cells possess functional characteristics of innate immune cells, as they can present Ag to T cells and can be stimulated with microbial molecules such as TLR ligands. Because crude preparations of Staphylococcus aureus are frequently used as polyclonal B cell activators and contain potent TLR2 activity, the scope of this study was to analyze the impact of S. aureus-derived TLR2-active substances on human B cell activation. Peripheral B cells stimulated with chemically modified S. aureus cell wall preparations proliferated in response to stimulation with crude cell wall preparations but failed to be activated with pure peptidoglycan, indicating that cell wall molecules other than peptidoglycan are responsible for B cell proliferation. Subsequent analysis revealed that surface protein A (SpA), similar to BCR cross-linking with anti-human Ig, sensitizes B cells for the recognition of cell wall-associated TLR2-active lipopeptides (LP). In marked contrast to TLR7- and TLR9-triggered B cell stimulation, stimulation with TLR2-active LP and SpA or with crude cell wall preparations failed to induce IgM secretion, thereby revealing qualitative differences in TLR2 signaling compared with TLR7/9 signaling. Notably, combined stimulation with SpA plus TLR2 ligands induced vigorous proliferation of a defined B cell subset that expressed intracellular IgM in the presence of IL-2.


CONCLUSIONS
S. aureus triggers B cell activation via SpA-induced sensitization of B cells for TLR2-active LP. Combined SpA and TLR2-mediated B cell activation promotes B cell proliferation but fails to induce polyclonal IgM secretion as seen after TLR7 and TLR9 ligation.
Bekeredjian-Ding
Isabelle
I
Department of Microbiology, University of Heidelberg, Im Neuenheimer Feld 324, Heidelberg, Germany. isabelle.bekeredjian-ding@med.uni-heidelberg.de
Inamura
Seiichi
S
Giese
Thomas
T
Moll
Hermann
H
Endres
Stefan
S
Sing
Andreas
A
Zähringer
Ulrich
U
Hartmann
Gunther
G
D001402:B-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation / Q000187:drug effects; D002473:Cell Wall / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D008024:Ligands; D008074:Lipoproteins / Q000276:immunology* / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D010455:Peptides / Q000276:immunology* / Q000494:pharmacology; D011940:Receptor Aggregation / Q000276:immunology; D011947:Receptors, Antigen, B-Cell / Q000819:agonists / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D013205:Staphylococcal Protein A / Q000276:immunology* / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000737:chemistry / Q000276:immunology*; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000276:immunology*; D051199:Toll-Like Receptor 7 / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000276:immunology
D007075:Immunoglobulin M; D008024:Ligands; D008074:Lipoproteins; D010455:Peptides; D011947:Receptors, Antigen, B-Cell; D013205:Staphylococcal Protein A; C495342:TLR2 protein, human; C495348:TLR7 protein, human; C495371:TLR9 protein, human; D051195:Toll-Like Receptor 2; D051199:Toll-Like Receptor 7; D051217:Toll-Like Receptor 9